Introduction
============

Wilms tumor, which is the common name for nephroblastoma, has been recognized as one of the most prevalent pediatric malignancies in childhood cancer, generally developing in children under 5 years of age and morphologically resembling embryonic kidney [@B1]-[@B3]. It constitutes approximately 8% of all cancers among children younger than 15 years in Western populations [@B4]. In Western populations, the occurrence rate of Wilms tumor is approximately 1/8,000 children [@B5], while the rate is approximately 3.3 cases per million in China [@B6]. Approximately 2% of Wilms tumor patients have a family history, and they are generally diagnosed as known causal genetic damage [@B7], [@B8]. However, no more than 5% of cases can be attributed to known causes, and the genetic basis underlying most Wilms tumor is not well understood [@B9]. Therefore, for Wilms tumor prevention and early diagnosis, it is important to identify risk factors and biomarkers that are associated with disease susceptibility to screen high-risk populations.

Genome-wide association study (GWAS) is a useful method employed without a hypothesis to find associations between susceptible genes and complex diseases, including tumors [@B9]. Previous GWASs and case-control studies have discovered several inherited susceptibility genes, such as *FWT1* [@B10], *FWT2* [@B11], *BRCA2* [@B12], *TP53* [@B13], [@B14], *BARD1* [@B15], *CTR9* [@B16], *hOGG1* and *FEN1* [@B17], and *XPD* [@B18] that are significantly associated with the risk of Wilms tumor. To date , no polymorphisms within lncRNAs and Wilms tumor risk have been reported, despite their implication in carcinogenesis as either proto-oncogenes or an anti-oncogenes [@B19]. Recently, we validated a critical susceptibility gene LIM domain only 1 (*LMO1*) [@B20] in a hospital-based, case-control study with a total of 145 Wilms tumor children and 531 cancer-free children, one of the members of the *LMO* gene super-family. The cysteine-rich transcriptional regulator is encoded by 11p15 in the *LMO1* gene, comprising two LIM zinc-binding domains. The *LMO1* gene is mainly concentrated in the nervous system and participates in the development of the nervous system [@B21]. Overexpression of *LMO1* was initially found in patients with T-cell acute lymphoblastic leukemia [@B22].

In our previous study, four GWAS-identified *LMO1* gene polymorphisms (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) were found to be associated with Wilms tumor susceptibility, but only the rs110419 A\>G polymorphism may reduce the susceptibility to Wilms tumor [@B20]. Thus, other *LMO1* gene polymorphisms require further determination to investigate Wilms tumor susceptibility. With this in mind, we carried out the current hospital-based case-control study with the same 145 Wilms tumor-bearing children and 531 cancer-free children to explore the association between five potentially functional polymorphisms in the *LMO1* gene \[rs2168101 G\>T (a super-enhancer polymorphism identified by Oldridge et al.) [@B23], rs1042359 A\>G, rs11041838 G\>C, rs2071458 C\>A and rs3750952 G\>C\] and Wilms tumor susceptibility in a southern Chinese population.

Materials and methods
=====================

Study subjects
--------------

Detailed information on the recruitment criteria has been reported previously [@B15], [@B24]-[@B26]. From March 2001 to June 2016, we recruited 145 Wilms tumor patients from the Department of Pediatric Urology of the Guangzhou Women and Children Medical Center. Moreover, 531 cancer-free children from the same hospital who had undergone routine physical examinations were randomly selected as controls [@B27]-[@B30]. All subjects were non-individual Han genetic individuals in South China. The response rate was approximately 90% for Wilms tumor patients and 95% for cancer-free controls. The Institutional Review Board of Guangzhou Women and Children\'s Medical Center approved this study, and each participant\'s parent or legal guardian provided medical informed consent.

Polymorphism analysis
---------------------

Approximately 2 mL of peripheral blood was collected from each subject for DNA extraction. Five *LMO1* potentially functional gene polymorphisms (rs2168101 G\>T, rs1042359 A\>G, rs11041838 G\>C, rs2071458 C\>A and rs3750952 G\>C) were chosen for genotyping [@B31]. Genomic DNA was isolated from peripheral blood leukocytes through a TIANamp Blood DNA Kit (TianGen Biotech, Beijing, China). A 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) and TaqMan real-time PCR were used in the *LMO1* gene polymorphism genotyping, as described in previous articles [@B32]-[@B35]. To acquire reliable results, we performed the genotyping blindly without knowledge of whether the subject was a case or control subject. Moreover, 10% of the samples were selected randomly for repeated assays, and the genotype concordance was 100%.

Statistical analysis
--------------------

The χ^2^ test was used to compare differences in the frequency distributions of demographic characteristics between cases and controls. The Hardy-Weinberg equilibrium for the genotype frequencies in controls was detected with a goodness-of-fit χ^2^ test. To further explore the associations between *LMO1* polymorphisms and Wilms tumor susceptibility, we calculated the odds ratio (OR) and the 95% confidence interval (CI) using non-conditional logistic regression and adjusting for age and gender. All tests were two-sided. *P*\<0.05 was considered statistically significant. All statistical analyses were performed with SAS software (Version 9.4; SAS Institute, Cary, NC).

Results
=======

Population characteristics
--------------------------

Overall, 145 patients with Wilms tumor and 531 cancer-free children were included in our analysis. The demographic characteristics of the Wilms tumor children and the cancer-free children are presented in **Supplementary Table [1](#SM0){ref-type="supplementary-material"}**. The mean age of the children with Wilms tumor was 26.17±21.48 months, and the mean age of the cancer-free children was 29.73±24.86 months. There was no significant difference in the age (*P*=0.725) or gender (*P*=0.956) distributions between patients and controls. According to the National Wilms Tumor Study-5 criteria [@B36], the clinical stages of the patients were divided into stages I-IV and \'not available\', corresponding to 4 (2.76%), 49 (33.79%), 50 (34.48%), 33 (22.76%), and 9 (6.21%) cases, respectively.

Associations between *LMO1* gene polymorphisms and Wilms tumor susceptibility
-----------------------------------------------------------------------------

The genotype frequencies of the five selected *LMO1* gene polymorphisms and their associations with Wilms tumor susceptibility are presented in **Table [1](#T1){ref-type="table"}**. We observed that the frequency distributions of all of the*LMO1* polymorphisms were consistent with the Hardy-Weinberg equilibrium (*P*=0.670 for rs2168101 G\>T, *P*=0.065 for rs1042359 A\>G, *P*=0.448 for rs11041838 G\>C, *P*=0.911 for rs2071458 C\>A and *P*=0.994 for rs3750952 G\>C polymorphism) in controls. Among the five polymorphisms, we observed that the rs2168101 G\>T polymorphism corresponded to a significant decrease in Wilms tumor susceptibility (GT vs. GG: adjusted OR=0.58, 95% CI=0.39-0.38, *P*=0.010; and GT/TT vs. GG: adjusted OR=0.67, 95% CI=0.46-0.97, *P*=0.034). However, no associations were found between the other four polymorphisms and Wilms tumor susceptibility. When these five polymorphisms of protective genotypes were combined, we found that the individuals with the five protective genotypes had reduced Wilms tumor susceptibility compared with those with 0-2 protective genotypes (adjusted OR=0.64, 95% CI=0.43-0.94, *P*=0.022).

Stratification analysis
-----------------------

We performed an analysis stratified by age, gender, and clinical stages to further evaluate the combined effect of *LMO1* gene polymorphisms (rs2168101 G\>T and rs2071458 C\>A) and the susceptibility of Wilms tumors given protective genotypes (**Table [2](#T2){ref-type="table"}**). Compared to the rs2168101 GG genotype, the protective effect of the GT/TT genotype was more predominant in males (adjusted OR=0.50, 95% CI=0.30-0.84, *P*=0.009). Nevertheless, the rs2071458 CA/AA genotype was more predominant in females (adjusted OR=0.36, 95% CI=0.19-0.70, *P*=0.003). In addition, the combined analysis indicated that the 3-5 protective genotypes obviously decreased Wilms tumor susceptibility in females (adjusted OR=0.55, 95% CI=0.30-0.99, *P*=0.045).

Genotype-based mRNA expression analysis
---------------------------------------

As shown in **Figure [1](#F1){ref-type="fig"}**, the rs2168101 G\>T polymorphism was also associated with altered *LMO1* mRNA expression in skeletal muscle tissues based on the public database GTEx Portal (<http://www.gtexportal.org/home/>) [@B18], [@B37].

Discussion
==========

In the current hospital-based case-control study, we explored the association of five *LMO1* gene polymorphisms with Wilms tumor susceptibility in 145 patients and 531 cancer-free controls. Although an association between *LMO1* gene polymorphisms and Wilms tumor susceptibility in Chinese children has been reported by our team, there are many more *LMO1* gene polymorphisms worthy of exploration. In this study, we verified that the super-enhancer rs2168101 G\>T polymorphism was significantly associated with a decreased risk of Wilms tumor, which was similar to the trend for neuroblastoma [@B23], [@B31].

On the basis of GWAS research, there is growing evidence that *LMO1* is a significant determinant of cancer susceptibility. Wang et al. identified that four genetic variants of *LMO1* (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) contributed to tumorigenesis ability in neuroblastoma among individuals of European descent [@B38]. Subsequently, this *LMO1* gene polymorphism susceptibility was further confirmed in five other epidemiological studies of different ethnicities [@B39]-[@B43]. Apart from neuroblastoma, *LMO1* gene polymorphisms were also associated with acute lymphoblastic leukemia susceptibility. In Caucasian children (163 patients and 251 controls), Beuten et al. found an association between another genotype of the *LMO1* gene (rs442264 A\>G) and susceptibility to acute lymphocytic leukemia [@B44]. In addition, recent studies have indicated that in anti-EGFR therapy, overexpression of *LMO1* may be a predictive marker for colorectal cancer [@B45], lung cancer [@B46] and prostate cancer [@B47].

The associations of the *LMO1* gene polymorphisms (rs110419 A\>G, rs4758051 G\>A, rs10840002 A\>G and rs204938 A\>G) with Wilms tumor susceptibility were reported in our previous study. Here, we performed a further study on the associations between five *LMO1* gene polymorphisms (rs2168101 G\>T, rs1042359 A\>G, rs11041838 G\>C, rs2071458 C\>A and rs3750952 G\>C) and Wilms tumor susceptibility in 145 patients and 531 healthy controls. We found that the GT/TT genotypes of the rs2168101 G\>T polymorphism correspond to a significant decrease in Wilms tumor susceptibility, while we failed to detect significant associations between the other four polymorphisms and Wilms tumor susceptibility. The rs2168101 GT/TT genotypes carriers had a significantly decreased Wilms tumor risk. The protective effects of this SNP may be ascribed to the lower expression of *LMO1* gene which is confirmed by Oldridge et al. [@B23] as well as data from GTEx database. Among these five polymorphisms we observed, the rs2168101 G\>T polymorphism corresponded to a significant decrease in Wilms tumor susceptibility only for the rs2168101 GT carriers compared with the GG carriers, suggesting a protective effect of this polymorphism against Wilms tumor. There did not seem to be an association between the other four polymorphisms and Wilms tumor susceptibility. The relatively small sample size of this current study might have limited the statistical power for detecting a difference. Non-significant SNPs in the single locus analysis may collectively modify Wilms tumor susceptibility. Not surprisingly, the combined analysis indicated that 3-5 protective genotypes obviously decreased Wilms tumor susceptibility in females. However, there is still no direct evidence showing the exact association of *LMO1* gene polymorphisms (rs2168101 G\>T and rs2071458 C\>A) with gender and clinical stage.

Several potential limitations of the current study may be ascribed to the following: 1) the relatively small sample size and lacking of multi-center clinical study, 2) the consideration of only five polymorphisms that lack potential function, and 3) the influence of environmental factors on Wilms tumor susceptibility.

In conclusion, we verified that the *LMO1* super-enhancer rs2168101 G\>T polymorphism was also significantly associated with a decreased risk of Wilms tumor.
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###### 

Genotype frequencies of *LMO1* gene polymorphisms and Wilms tumor susceptibility

  Genotype                                          Cases (N=145)   Controls (N=531)   *P*^a^      Crude OR (95% CI)      *P*         Adjusted OR (95% CI) ^b^   *P*^b^
  ------------------------------------------------- --------------- ------------------ ----------- ---------------------- ----------- -------------------------- -----------
  **rs2168101 G\>T (HWE=0.670)**                                                                                                                                 
  GG                                                90 (62.07)      275 (51.79)                    1.00                               1.00                       
  GT                                                41 (28.28)      217 (40.87)                    **0.58 (0.38-0.87)**   **0.009**   **0.58 (0.39-0.88)**       **0.010**
  TT                                                14 (9.66)       39 (7.34)                      1.10 (0.57-2.11)       0.782       1.14 (0.59-2.20)           0.702
  Additive                                                                             **0.021**   0.82 (0.61-1.10)       0.182       0.83 (0.61-1.12)           0.214
  Dominant                                          55 (37.93)      256 (48.21)        **0.028**   **0.66 (0.45-0.96)**   **0.028**   **0.67 (0.46-0.97)**       **0.034**
  Recessive                                         131 (90.34)     492 (92.66)        0.359       1.35 (0.71-2.56)       0.360       1.40 (0.73-2.66)           0.310
  **rs1042359 A\>G (HWE=0.065)**                                                                                                                                 
  AA                                                130 (89.66)     485 (91.34)                    1.00                               1.00                       
  AG                                                14 (9.66)       43 (8.10)                      1.22 (0.65-2.29)       0.547       1.21 (0.64-2.28)           0.564
  GG                                                1 (0.69)        3 (0.56)                       1.24 (0.13-12.06)      0.851       1.13 (0.12-11.03)          0.915
  Additive                                                                             0.822       1.19 (0.68-2.08)       0.540       1.17 (0.67-2.04)           0.582
  Dominant                                          15 (10.34)      46 (8.66)          0.531       1.22 (0.66-2.25)       0.532       1.20 (0.65-2.22)           0.561
  Recessive                                         144 (99.31)     528 (99.44)        0.862       1.22 (0.13-11.84)      0.863       1.11 (0.11-10.84)          0.927
  **rs11041838 G\>C (HWE=0.448)**                                                                                                                                
  GG                                                100 (68.97)     386 (72.69)                    1.00                               1.00                       
  GC                                                39 (26.90)      136 (25.61)                    1.11 (0.73-1.68)       0.634       1.11 (0.73-1.68)           0.638
  CC                                                6 (4.14)        9 (1.69)                       2.57 (0.90-7.40)       0.079       2.51 (0.87-7.23)           0.088
  Additive                                                                             0.187       1.26 (0.89-1.79)       0.194       1.26 (0.89-1.78)           0.203
  Dominant                                          45 (31.03)      145 (27.31)        0.376       1.20 (0.80-1.79)       0.377       1.20 (0.80-1.78)           0.385
  Recessive                                         139 (95.86)     522 (98.31)        0.077       2.50 (0.88-7.15)       0.087       2.44 (0.85-6.99)           0.096
  **rs2071458 C\>A (HWE=0.911)**                                                                                                                                 
  CC                                                101 (69.66)     324 (61.02)                    1.00                               1.00                       
  CA                                                38 (26.21)      181 (34.09)                    0.67 (0.45-1.02)       0.062       0.69 (0.45-1.04)           0.078
  AA                                                6 (4.14)        26 (4.90)                      0.74 (0.30-1.85)       0.520       0.71 (0.28-1.78)           0.462
  Additive                                                                             0.159       0.75 (0.53-1.04)       0.086       0.75 (0.54-1.05)           0.090
  Dominant                                          44 (30.34)      207 (38.98)        0.056       0.68 (0.46-1.01)       0.057       0.69 (0.47-1.03)           0.067
  Recessive                                         139 (95.86)     505 (95.10)        0.703       0.84 (0.34-2.08)       0.703       0.79 (0.32-1.97)           0.619
  **rs3750952 G\>C (HWE=0.994)**                                                                                                                                 
  GG                                                78 (53.79)      253 (47.65)                    1.00                               1.00                       
  GC                                                51 (35.17)      227 (42.75)                    0.73 (0.49-1.08)       0.117       0.74 (0.50-1.10)           0.137
  CC                                                16 (11.03)      51 (9.60)                      1.02 (0.55-1.89)       0.956       1.06 (0.57-1.97)           0.860
  Additive                                                                             0.259       0.90 (0.68-1.19)       0.446       0.91 (0.69-1.21)           0.524
  Dominant                                          67 (46.21)      278 (52.35)        0.189       0.78 (0.54-1.13)       0.190       0.80 (0.55-1.15)           0.229
  Recessive                                         129 (88.97)     480 (90.40)        0.610       1.17 (0.64-2.12)       0.610       1.21 (0.66-2.19)           0.538
  **Combined effect of protective genotypes ^c^**                                                                                                                
  0-2                                               55 (37.93)      146 (27.50)                    1.00                               1.00                       
  3-5                                               90 (62.07)      385 (72.50)        **0.015**   **0.62 (0.42-0.91)**   **0.015**   **0.64 (0.43-0.94)**       **0.022**

^a^ *χ^2^* test for genotype distributions between Wilms tumor patients and controls. ^b^ Adjusted for age and gender. ^c^ The protective genotypes were carriers with rs2168101 GT/TT, rs1042359 AG/AA, rs11041838 GC/GG, rs2071458 CA/AA and rs3750952 GC/CC genotypes.

###### 

Stratification analysis of risk genotypes with Wilms tumor susceptibility

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables             rs2168101\         Adjusted OR ^a^\   *P* ^a^                rs2071458\         Adjusted OR ^a^\   *P* ^a^   Combined genotypes\    Adjusted OR ^a^\   *P* ^a^                                   
                        (cases/controls)   (95% CI)                                  (cases/controls)   (95% CI)                     (cases/controls)       (95% CI)                                                     
  --------------------- ------------------ ------------------ ---------------------- ------------------ ------------------ --------- ---------------------- ------------------ --------- -------- ---------------------- -----------
  **Age, month**                                                                                                                                                                                                         

  ≤18                   44/128             22/105             0.60 (0.34-1.07)       0.085              44/139             22/94     0.75 (0.42-1.33)       0.316              26/66     40/167   0.61 (0.35-1.09)       0.094

  \>18                  46/147             33/151             0.70 (0.42-1.15)       0.157              57/185             22/113    0.64 (0.37-1.10)       0.104              29/80     50/218   0.62 (0.37-1.06)       0.079

  **Gender**                                                                                                                                                                                                             

  Females               36/126             28/107             0.93 (0.53-1.62)       0.793              51/136             13/97     **0.36 (0.19-0.70)**   **0.003**          24/57     40/176   **0.55 (0.30-0.99)**   **0.045**

  Males                 54/149             27/149             **0.50 (0.30-0.84)**   **0.009**          50/188             31/110    1.08 (0.65-1.80)       0.760              31/89     50/209   0.71 (0.42-1.18)       0.188

  **Clinical stages**                                                                                                                                                                                                    

  I                     3/275              1/256              0.37 (0.04-3.57)       0.387              3/324              1/207     0.61 (0.06-6.02)       0.673              2/146     2/385    0.45 (0.06-3.29)       0.432

  II                    32/275             17/256             0.59 (0.32-1.10)       0.098              34/324             15/207    0.70 (0.37-1.33)       0.274              20/146    29/385   0.57 (0.31-1.04)       0.068

  III                   27/275             23/256             0.91 (0.51-1.63)       0.758              38/324             12/207    **0.49 (0.25-0.96)**   **0.038**          22/146    28/385   **0.47 (0.26-0.86)**   **0.014**

  IV                    21/275             12/256             0.60 (0.29-1.25)       0.175              21/324             12/207    0.91 (0.44-1.88)       0.789              8/146     25/385   1.22 (0.53-2.77)       0.642

  I+II                  35/275             18/256             0.58 (0.32-1.05)       0.071              37/324             16/207    0.69 (0.37-1.28)       0.241              22/146    31/385   0.56 (0.31-1.00)       0.052

  III+IV                48/275             35/256             0.78 (0.49-1.24)       0.294              59/324             24/207    0.63 (0.38-1.05)       0.078              30/146    53/385   0.67 (0.41-1.09)       0.108
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Adjusted for age and gender, omitting the corresponding stratification factor.
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